Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 RA Beta Cell Function in T2DM
NCT04135287Phase 4Unknown
- Sponsor
- Dasman Diabetes Institute
- Start
- Mar 2020
- Primary completion
- Mar 2023
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of exenatide, liraglutide, dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Dasman Diabetes Institute. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04135287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135287.